The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma

Clinical and Experimental Allergy

Volumn 44, Issue 9, 2014, Pages 1146-1153

  Leaker, B R ^a   Barnes, P J ^b   O'Connor, B J ^a   Ali, F Y ^a   Tam, P ^c   Neville, J ^c   Mackenzie, L F ^c   Macrury, T ^c  

^a RESPIRATORY CLINICAL TRIALS LTD   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c Aquinox Pharmaceuticals   (Canada)

Author keywords

Airway hyperresponsiveness; Asthma; Induced sputum; Inhaled allergen challenge; Phosphoinositide 3 kinase; SH2 containing inositol 5 phosphatase 1

Indexed keywords

ANTIASTHMATIC AGENT; AQX 1125; METHACHOLINE; NITRIC OXIDE; PHOSPHATASE; PLACEBO; SH2 CONTAINING INOSITOL 5 PHOSPHATASE 1; UNCLASSIFIED DRUG; 4-(4-(AMINOMETHYL)-7A-METHYL-1-METHYLIDENEOCTAHYDRO-1H-INDEN-5-YL)-3-(HYDROXYMETHYL)-4-METHYLCYCLOHEXAN-1-OL; ALLERGEN; CYCLOHEXANOL DERIVATIVE; INDAN DERIVATIVE; INOSITOL-POLYPHOSPHATE 5-PHOSPHATASE; PHOSPHATIDYLINOSITOL;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DYSPEPSIA; EOSINOPHIL; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUTROPHIL; PHOSPHOINOSITIDE METABOLISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM ANALYSIS; TREATMENT RESPONSE; ANALYSIS OF VARIANCE; CLINICAL TRIAL; EXHALATION; FEMALE; IMMUNOLOGY; INHALATION TEST; MALE; METABOLISM; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SPUTUM; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ALLERGENS; ANALYSIS OF VARIANCE; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHIAL PROVOCATION TESTS; CROSS-OVER STUDIES; CYCLOHEXANOLS; EXHALATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; MALE; NITRIC OXIDE; PHOSPHATIDYLINOSITOLS; PHOSPHORIC MONOESTER HYDROLASES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SPUTUM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906237265     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12370     Document Type: Article

References (31)

1. GINA global strategy for asthma management and prevention. http://www.ginasthma.org/local/uploads/files/GINA_Report_March13.pdf
2. Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006; 6:13.
3. Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study Am J Respir Crit Care Med 2004; 170:836-44.
4. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008; 8:183-92.
5. Helgason CD, Damen JE, Rosten P et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev 1998; 12:1610-20.
6. Ong CJ, Ming-Lum A, Nodwell M et al. Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. Blood 2007; 110:1942-9.
7. Krystal G. Lipid phosphatases in the immune system. Semin Immunol 2000; 12:397-403.
8. March ME, Ravichandran K. Regulation of the immune response by SHIP. Semin Immunol 2002; 14:37-47.
9. Parry RV, Harris SJ, Ward SG. Fine tuning T lymphocytes: a role for the lipid phosphatase SHIP1. Biochim Biophys Acta 2010; 1804:592-7.
10. Ooms LM, Horan KA, Rahman P et al. The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease. Biochem J 2009; 419:29-49.
11. Stenton GR, Mackenzie LF, Tam P et al. Characterization of AQX-1125, a small-molecule SHIP1 activator: part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo. Br J Pharmacol 2013; 168:1519-29.
12. Singh D, Richards D, Knowles RG et al. Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. Am J Respir Crit Care Med 2007; 176:988-93.
13. Singh D, Petavy F, MacDonald AJ, Lazaar AL, O'Connor BJ. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res 2010; 11:26.
14. Pizzichini E, Pizzichini MM, Efthimiadis A et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996; 154:308-17.
15. Joos GF, O'Connor B, Anderson SD et al. Indirect airway challenges. Eur Respir J 2003; 21:1050-68.
16. Baran CP, Tridandapani S, Helgason CD, Humphries RK, Krystal G, Marsh CB. The inositol 5′-phosphatase SHIP1 and the Src kinase Lyn negatively regulate macrophage colony-stimulating factor-induced Akt activity. J Biol Chem 2003; 278:38628-36.
17. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129:1261-74.
18. Stenton GR, Mackenzie LF, Tam P et al. Characterization of AQX-1125, a small-molecule SHIP1 activator: part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo. Br J Pharmacol 2013; 168:1506-18.
19. Harbinson PL, MacLeod D, Hawksworth R et al. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur Respir J 1997; 10:1008-14.
20. van Schalkwyk E, Strydom K, Williams Z et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 2005; 116:292-8.
21. Palmqvist M, Bruce C, Sjöstrand M, Arvidsson P, Lötvall J. Differential effects of fluticasone and montelukast on allergen-induced asthma. Allergy 2005; 60:65-70.
22. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370:1422-31.
23. Duong M, Gauvreau G, Watson R et al. The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. J Allergy Clin Immunol 2007; 119:322-7.
24. Gauvreau GM, Boulet LP, Postma DS et al. Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. J Allergy Clin Immunol 2005; 116:285-91.
25. Inman MD, Watson RM, Rerecich T et al. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med 2001; 164:569-74.
26. Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008; 155:308-15.
27. Diamant Z, Sidharta PN, Singh D, et al. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy 2014; 44:1044-52.
28. Peter D, Jin SL, Conti M, Hatzelmann A, Zitt C. Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol 2007; 178:4820-31.
29. O'Byrne PM. Allergen-induced airway inflammation and its therapeutic intervention. Allergy Asthma Immunol Res 2009; 1:3-9.
30. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352:2163-73.
31. Kanniess F, Richter K, Böhme S, Jörres RA, Magnussen H. Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J 2002; 20:853-8.